PHGN Stock Chart & Stats
€1.10
-€0.04(-3.84%)
At close: 4:00 PM EDT
€1.10
-€0.04(-3.84%)
Day’s Range― - ―
52-Week Range€0.60 - €1.78
Previous CloseN/A
Volume580.00
Average Volume (3M)11.21K
Market Cap
€711.67M
Enterprise Value€934.02
Total Cash (Recent Filing)€158.25M
Total Debt (Recent Filing)€126.73M
Price to Earnings (P/E)79.8
Beta0.52
Next Earnings
Nov 05, 2026EPS Estimate
<0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.01
Shares Outstanding707,781,250
10 Day Avg. Volume3,832
30 Day Avg. Volume11,210
Financial Highlights & Ratios
PEG Ratio-2.78
Price to Book (P/B)3.72
Price to Sales (P/S)2.74
P/FCF Ratio20.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.02
Revenue Forecast (FY)€390.63M
Bulls Say, Bears Say
Bulls Say
Joenja Growth And Market ExpansionStrong Joenja growth, rising patient identification and international launches support a durable second product franchise. Pediatric label expansion could broaden access further, reducing reliance on RUCONEST and strengthening long-term revenue diversification.
High Gross Margins And Cost DisciplineThe specialty-medicine model supports substantial gross profit retention, while lower operating-expense guidance shows management is controlling the cost base. This provides funding capacity for pipeline investment and greater resilience as revenue scales.
Recovery In Profitability And LeverageA return to positive earnings and cash generation marks a meaningful recovery from 2023–2024 losses. Improved leverage and reasonable earnings quality enhance financial flexibility, helping Pharming fund operations and development without an overly aggressive capital structure.
Bears Say
Revenue Slowdown And Reduced GuidanceThe guidance reduction and falling first-half revenue indicate that near-term growth has weakened materially. Slower expansion limits operating leverage and leaves less room for execution setbacks while the company invests heavily in future products.
RUCONEST Competitive PressureRUCONEST remains a major commercial product, but competition from an oral therapy is pressuring sales and patient dynamics. Even if performance stabilizes, sustained competitive intensity could constrain the established franchise and increase reliance on Joenja.
Volatile Cash Generation And Thin MarginsRecent operating cash outflows and lower TTM free cash flow show that cash conversion can fluctuate with working capital and investment needs. Thin net margins provide limited protection if sales soften or R&D and manufacturing costs remain elevated.
Pharming Group News
PHGN FAQ
What was Pharming Group’s price range in the past 12 months?
Pharming Group lowest stock price was €0.60 and its highest was €1.78 in the past 12 months.
What is Pharming Group’s market cap?
Pharming Group’s market cap is €711.67M.
When is Pharming Group’s upcoming earnings report date?
Pharming Group’s upcoming earnings report date is Nov 05, 2026 which is in 70 days.
How were Pharming Group’s earnings last quarter?
Pharming Group released its earnings results on Jul 30, 2026. The company reported €0.002 earnings per share for the quarter, missing the consensus estimate of €0.005 by -€0.003.
Is Pharming Group overvalued?
According to Wall Street analysts Pharming Group’s price is currently Overvalued.
Does Pharming Group pay dividends?
Pharming Group does not currently pay dividends.
What is Pharming Group’s EPS estimate?
Pharming Group’s EPS estimate is <0.01.
How many shares outstanding does Pharming Group have?
Pharming Group has 707,781,250 shares outstanding.
What happened to Pharming Group’s price movement after its last earnings report?
Pharming Group reported an EPS of €0.002 in its last earnings report, missing expectations of €0.005. Following the earnings report the stock price went down -20.364%.
Which hedge fund is a major shareholder of Pharming Group?
Currently, no hedge funds are holding shares in DE:PHGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Pharming Group
Based in Leiden, the Netherlands, Pharming Group N.V. operates as a biopharmaceutical firm dedicated to advancing and marketing protein replacement therapies and precise medical solutions. Its global efforts, spanning the United States, Europe, and other international markets, focus on addressing rare diseases and critical unmet medical needs. The company's flagship product, Ruconest, is a recombinant human C1 esterase inhibitor prescribed for managing acute attacks of hereditary angioedema. Pharming's development pipeline also encompasses rhC1INH, which is under investigation for potential applications in pre-eclampsia, acute kidney injury, and COVID-19. Furthermore, they are progressing leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) inhibitor, for individuals afflicted with activated PI3K delta syndrome, as well as an alpha-glucosidase therapy aimed at treating Pompe and Fabry diseases. The company maintains significant partnerships, including a development and license agreement with Novartis and a strategic alliance with Orchard Therapeutics plc. This latter collaboration involves the research, development, manufacture, and commercialization of OTL-105, an experimental ex-vivo autologous hematopoietic stem cell gene therapy designed to treat hereditary angioedema.
PHGN Company Deck
PHGN Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a mix of meaningful commercial and clinical positives—most notably strong Joenja growth, resilient RUCONEST patient metrics, and near‑term clinical catalysts—against tangible near‑term headwinds including a $30M revenue guidance reduction, RUCONEST year‑over‑year sales decline, manufacturing inventory impairments, and operating cash outflows. Management emphasized cost discipline, maintained positive operating profitability in the quarter, and outlined multiple growth levers (pediatric and geographic expansion for Joenja, two Phase II readouts in Q4, and a 2027 pivotal readout for napazimone). Given the balance of clear growth drivers and pipeline upside against notable short‑term financial and operational challenges, the tone is constructive but cautious.View all DE:PHGN earnings summaries